Anavex is also working on it
Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
Bristol Myers to acquire brain drug developer Karuna for $14B The deal would hand Bristol Myers an experimental treatment for schizophrenia that analysts think could become a blockbuster product. "...The acquisition hands Bristol Myers a closely watched medicine known as “KarXT” that’s currently being reviewed by the Food and Drug Administration as a potential treatment for schizophrenia. The drug is a newer type of medication that doesn’t work like available schizophrenia treatments...."